SPECTROFLUORIMETRIC METHOD FOR DETERMINATION OF LETROZOLE: ANALYTICAL APPLICATIONS TO BRAIN TISSUE SAMPLES AND ALKALINE DEGRADATION KINETIC STUDY
Abstract
A simple and sensitive spectroflourimetric method has been proposed for the determination of the antitumor agent letrozole in tablets, spiked human plasma, and rat brain tissue homogenates. Our method involves measuring the native fluorescence of letrozole at 590 nm upon excitation at 239 nm as indicated upon scanning its three-dimensional spectrum. Various experimental parameters were intensively studied and the method was validated as per ICH guidelines. The calibration curve was linear over the concentration range 5-160 ng/mL, with limit of detection 1.36 ng/mL. It was successfully applied to the analysis of letrozole in Femara® tablets with mean recovery 99.35 ± 1.49% and was further applied to study the alkaline degradation kinetics of letrozole. The pseudo first order rate constant and half-life were calculated. Moreover, Successful application of our proposed procedure was carried out on spiked human plasma and rat brain tissue samples. Linear ranges were found to be 5-30 and 10-130 ng/mL, with detection limits 1.25 and 1.71 ng/mL for plasma and brain samples, respectively. Thanks to the method's simplicity, selectivity, and high sensitivity, it can be used for routine analysis in quality control laboratories and for further clinical investigations involving letrozole.
About the Authors
A. M. El-Kosasy
Ain Shams University
Egypt
Egypt
Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy
CairoM. H. Abdel Rahman
Ain Shams University
Egypt
Egypt
Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy
CairoS. H. Abdelaal
Ain Shams University
Egypt
Egypt
Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy
CairoReferences
1. M. Sittig, Pharmaceutical Manufacturing Encyclopedia Textbook, 3 rd ed., William Andrew publishing, Norwich, New York (2013).
2. A. S. Bhatnagar, Breast Cancer Res. Treat., 105, 7–17 (2007).
3. J. Doiron, A. H. Soultan, R. Richard, M. M. Touré, N. Picot, R. Richard, M. Cuperlovi-Culf, G. A. Robichaud, M. Touaibi, Eur. J. Med. Chem., 46, 4010–4024 (2011).
4. W. R. Miller, Semin. Oncol., 14, 3–11 (2003).
5. R. Madhup, S. Kirti, M. L. B. Bhatt, P. K. Srivastava, M. Srivastava, S. Kumar, The Breast, 15, 440–442 (2006).
6. S. Goyal, T. Puri, P. K. Julka, G. K. Rath, Acta Neurochir, 150, 613–615 (2008).
7. N. Dave, G. A. Gudelsky, P. B. Desai, Cancer Chemother. Pharmacol., 72, 349–357 (2013).
8. N. Dave, L. M. L. Chow, G. A. Gudelsky, K. LaSance, X. Qi, P. B. Desai, Mol. Cancer Ther., 14, 857–864 (2015).
9. N. Mondal, T. K. Pal, S. K. Ghosal, Pharmazie, 62, 597–598 (2007).
10. M. Ganesh, K. Kamalakannan, R. Patil, S. Upadhyay, A. Srivatsava, T. Sivakumar, S. Ganguly, Rasayan J. Chem., 1, 55–58 (2008)
11. S. K. Acharjya, P. Mallick, P. Panda, K. R. Kumar, M. M. Annapurna. J. Adv. Pharm. Tech. Res., 1, 348–353 (2010)
12. A. Rusu, M. A. Sbanca, N. Todoran, C. E. Vari, Acta Med. Marisiensis, 63, 80–86 (2017)
13. C. U. Pfister, M. Duval, J. Godbillon, G. Gosset, D. Gygax, F. Marfil, A. Sioufi, B. Winkler, Int. J. Pharm. Sci., 83, 520–524 (1994).
14. N. Mondal, T. K. Pal, S. K. Ghosal, Acta Pol. Pharm., 66, 11–17 (2009).
15. M. Ganesh, K. Rajasekar, M. Bhagiyalakshmi, M. Vinoba, K. Saktimanigandan, H. T. Jang, Trop. J. Pharm. Res., 9, 505–510 (2010).
16. M. Rezaee, Y. Yamini, M. Hojjati, M. Faraji, Anal. Methods, 2, 1341–1345 (2010).
17. A. Shrivastava, A. K. Chakraborty, S. K. Rambhade, U. K. Patil, Pharm. Sin., 2, 263–269 (2011).
18. S. K. Acharjya, S. K. Bhattamisra, B. R. E. Muddana, R.V. V. Bera, P. Panda, B. P. Panda, G. Mishra, Sci. Pharm., 80, 941–953 (2012).
19. B. A. Moussa, R. I. El-Bagary, E. A. Osman, Anal. Chem. Lett., 3, 139–146 (2014).
20. F. Marfil, V. Pineau, A. Sioufi, J. Godbillon, J. Chromatogr. B, 683, 251–258 (1996).
21. A. Zarghi, S. M. Foroutan, A. Shafaati, A. Khoddam, Chromatographia, 66, 747–750 (2007).
22. J. Rodriguez, G. Castaneda, L. Munoz, J. Chromatogr. B, 913-914, 12–18 (2013).
23. B. Beer, B. Schubert, A. Oberguggenberger, V. Meraner, M. Hubalek, H. Oberacher, Anal. Bioanal. Chem., 398, 1791–1800 (2010).
24. J. C. Precht, B. Ganchev, G. Heinkele, H. Brauch, M. Schwab, T. E. Mürdter, Anal. Bioanal. Chem., 403, 301–308 (2012)
25. S. Gomes, Int. J. Adv. Res. Pharm. Biosci., 3, 84–94 (2013).
26. U. Mareck, G. Sigmund, G. Opfermann, H. Geyer, M. Thevis, W. Schanzer, Rapid Commun. Mass Spectrom., 19, 3689–3693 (2005).
27. J. J. Berzas, J. Rodriguez, A. M. Contento, M. P. Cabello, J. Sep. Sci., 26, 908–914 (2003).
28. J. R. Flores, A. M. C. Salcedo, M. J. V. Llerena, L. M. Fernandez, J. Chromatogr. A, 1185, 281–290 (2008).
29. J. R. Flores, A. M. C. Salcedo, L. M. Fernandez, Electrophoresis, 30, 624–632 (2009).
30. A. Rusu, G. Hancu, L. Berta, C. E. Vari, Studia Ubb Chemia, 3, 251–264 (2017).
31. P. Norouzi, M. R. Ganjali, M. Qomi, A. Nemati Kharat, H. A. Zamani, Chin. J. Chem., 28, 1133–1139 (2010).
32. M. R. Ganjali, A. Karimi, P. Norouzi, Int. J. Electrochem. Sci., 7, 3681–3692 (2012).
33. H. P. Ranaganathan, G. Govindrajulu, V. Palaniyappan, Int. J. Pharm. Pharm. Sci., 4, 582–586 (2012).
34. M. M. Annapurna, C. Mohapatro, A. Narendo, J. Pharm. Anal., 2, 298–305 (2012).
35. E. F. Elkady, M. A. Fouad, Pak. J. Pharm. Sci., 28, 2041–2051 (2015).
36. ICH Harmonised Tripartite Guideline. Validation of Analytical Procedures: Text and Methodology, Q2 (R1). Geneva (2005); http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1_Guideline.pdf. [Accessed 15 December 2016].
37. H. M. Lamb, J. C. Adkins, Drugs, 56, 1125–1140 (1998).
38. A. H. Zawaneh, N. N. Khalil, S. A. Ibrahim, W. N. Al Dafiri, H. M. Maher, Luminescence, 38, 1162–1168 (2017).
Review
For citations:
El-Kosasy A.M., Abdel Rahman M.H., Abdelaal S.H. SPECTROFLUORIMETRIC METHOD FOR DETERMINATION OF LETROZOLE: ANALYTICAL APPLICATIONS TO BRAIN TISSUE SAMPLES AND ALKALINE DEGRADATION KINETIC STUDY. Zhurnal Prikladnoii Spektroskopii. 2019;86(5):765-771.
Views: 299
Email this article 